ORB-011 is under clinical development by Orionis Biosciences and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ORB-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORB-011 is under development for the treatment of solid tumors including triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer squamous cell carcinoma, metastatic melanoma, bladder cancer, gastric cancer, transitional cell cancer (urothelial cell cancer), esophageal cancer, kidney cancer (renal cell cancer), ovarian cancer, liver cancer, colorectal cancer. It is administered through intravenous route.
Orionis Biosciences overview
Orionis Biosciences is a biotechnology company that discover and develops drugs for the treatment of oncology, immunotherapies and diseases with high unmet medical needs. The company is headquartered in Waltham, Massachusetts, the US.
For a complete picture of ORB-011’s drug-specific PTSR and LoA scores, buy the report here.